Trial Profile
Clinical phase II, multicenter, open trabectedin (Yondelis ®) in patients with advanced breast cancer, HER2 negative, hormone receptor-positive, with gene overexpression or subexpression class xeroderma pigmentosum G (XPG).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Sponsors PharmaMar
- 05 Oct 2021 this trial has been completed in Spain as per European Clinical Trials Database record.
- 17 Oct 2011 EudraCT identified as an additional source and identifiers, multiple endpoints and patient inclusion/exclusion criteria added
- 17 Oct 2011 Planned number of patients changed from 40 to 100.